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Genetic aberrationsAdvanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic chemotherapy have
plateaued. Recent technological advances allows for a comprehensive analysis of genomic alterations
in a timely manner. The Cancer Genome Atlas (TCGA) study revealed that there are numerous genomic
aberrations in muscle-invasive urothelial carcinoma, such as TP53, ARID1A, PIK3CA, ERCC2, FGFR3, and
HER2. Molecular targeted therapies against similar genetic alterations are currently available for other
malignancies, but their efﬁcacy in urothelial carcinoma has not been established. This review describes
the genomic landscape of malignant urothelial carcinomas, with an emphasis on the potential to prose-
cute these tumours by deploying novel targeted agents and immunotherapy in appropriately selected
patient populations.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Urothelial carcinoma (transitional cell carcinoma) is estimated
to cause 150,000 deaths (world-wide) per year [1]. This type of
cancer affects the urinary system, including the renal pelvis,
ureters, bladder, urethra, and urachus [2]. It is the most common
type of bladder cancer [2]. Approximately 75–80% of cases of
urothelial tumours present with non-muscle invasive disease;
however, the remaining cases of advanced (muscle-invasive) dis-
ease can show progression to metastatic disease that is often fatal.
Environmental carcinogens, such as tobacco, aromatic amines,
phenacetin, and arsenic, as well as chronic infection with
Schistosoma hematobium, and male gender, are known risk factors
[3,4]. Despite advances in treatment over past decades, therapy
for metastatic disease is still limited and often fails. Therefore, it
is important to consider alternative therapeutics in urothelial
malignancy.
Currently, the most commonly used approach for the manage-
ment of muscle-invasive urothelial carcinoma is multimodal ther-
apy that combines surgery, radiation, and chemotherapy (Table 1)
[5–12]. In muscle-invasive disease, neoadjuvant chemotherapy
with standard-dose M-VAC (methotrexate, vinblastine, doxoru-
bicin, and cisplatin) is the standard of care based on results fromprospective randomised phase III trials [5,6,13]. In the U.S. inter-
group trial (Table 1), the standard-dose M-VAC followed by radical
cystectomy for patients with muscle-invasive resulted in an
increase of 31 months in median overall survival (OS) compared
to the group without neoadjuvant chemotherapy (median OS:
77 months vs 46 months, P = 0.06 by a two-sided stratiﬁed
log-rank test) [5]. Another randomised phase III controlled trial
showed that neoadjuvant CMV (cisplatin, methotrexate, vin-
blastine) plus local therapy (either radical cystectomy or radiation)
yielded a 6% absolute 10-year OS beneﬁt compared to local therapy
alone (10-year OS, 36% vs 30%; HR 0.84; 95% conﬁdence interval
[CI], 0.72–0.99). Meta-analysis of platinum-based combination
neoadjuvant chemotherapy therapy showed about 5% absolute
OS beneﬁt at ﬁve years [14–16]. These studies established
cisplatin-based combination neoadjuvant therapy as the standard
of care in patients with muscle-invasive urothelial cancer.
Chemoradiation demonstrated survival beneﬁt in patients who
are not candidate for surgery [17].
Multiple regimens have also been developed to improve sur-
vival in patients with metastatic urothelial cancer. Phase I and
phase II trials with standard-dose M-VAC showed an overall
response rate (RR) of approximately 70%, including clinical com-
plete response (CR) in 36% of patients [18,19]. Subsequently, a
phase III trial was conducted to compare standard-dose M-VAC
and cisplatin alone or CISCA (cisplatin, cyclophosphamide, and
adriamycin). M-VAC was superior to either cisplatin alone or
CISCA, and showed an absolute OS beneﬁt of 3–4 months. [7,8] In
studies of a dose-dense regimen with growth factor support,
Table 1
Standard therapy for advanced urothelial carcinoma [5–12].
Stage Therapy Outcome P value
Muscle-invasive disease Standard dose-MVAC + radical cystectomy vs
radical cystectomy only [5]
Median OS: 77 mo vs 46 mo P = 0.06 (two-sided)
Cisplatin, methotrexate, and vinblastine + local
therapy vs local therapy only [6]
10 year OS: 36% vs 30% HR 0.84 (95% CI, 0.72–0.99)
Metastatic disease Standard dose-MVAC vs cisplatin [7] Median OS: 12.5 mo vs 8.2 mo P = 0.002
Standard dose-MVAC vs CISCA [8] Median OS: 12 mo vs 9 mo N/A
Standard dose-MVAC vs dose dense-MVAC [9,10] 5 year OS: 14% vs 22% P = 0.042
Standard dose-MVAC vs gemcitabine plus cisplatin [11] Median OS: 14.8 mo vs 13.8 mo P = 0.75
Gemcitabine plus cisplatin vs paclitaxel, gemcitabine, and cisplatin [12] Median OS: 12.7 mo vs 15.8 mo P = 0.75
Abbreviations: CISCA = cisplatin, cyclophosphamide, and adriamycin; CMV = cisplatin, methotrexate, and vinblastine; HR = hazard ratio; mo = months; M-
VAC = methotrexate, vinblastine, adriamycin, and cisplatin; N/A = not available; OS = overall survival; vs = versus.
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P = 0.009) and a superior RR (72% vs 58%, P = 0.016) compared to
standard-dose M-VAC [9,10]. Median OS was slightly improved in
the dose-dense regimen (15.1 months vs 14.9 months; HR 0.76,
95% CI: 0.58–0.99), and the 5-year survival rate was superior in
the dose-dense arm (26.2% vs 13.5%; 95% CI, 0.15–0.29). Grade 3
and grade 4 toxicities were less common in the dose-dense regi-
men, especially in neutrophil counts. In another study, the combi-
nation of gemcitabine and cisplatin was compared to
standard-dose M-VAC in a phase III setting with similar median
progression free survival (PFS) (7.4 months vs 7.4 months) and
median OS (13.8 months vs 14.8 months, P = 0.75), but with fewer
toxicities [20]. Addition of paclitaxel to the combination of gemc-
itabine and cisplatin resulted in a higher RR (55.5% vs 43.6%,
P = 0.0031), and higher toxicity but no OS beneﬁt (median OS,
15.8 months vs 12.7 months, P = 0.75) [12]. These studies estab-
lished the combination of gemcitabine and cisplatin or M-VAC as
the standard of therapy in metastatic urothelial carcinoma.
Although these results conﬁrm that the combination
chemotherapy improves outcomes, the overall beneﬁt is modest,
and alternative therapies are needed to signiﬁcantly improve the
prognosis of patients with metastatic urothelial carcinoma.
Deployment of immunotherapy or matched targeted therapy
approaches based on molecular proﬁles has resulted in signiﬁcant
beneﬁts to patients with a variety of cancers ranging from chronic
myelogenous leukaemia to lung cancer [21,22]. We therefore
reviewed the molecular landscape of urothelial carcinoma and its
implications for molecularly targeted and immunotherapeutic
approaches.Genomic alterations in urothelial malignancy
The advances in technology over recent decades have made it
possible to capture genomic alterations in cancer. In urothelial car-
cinoma, whole genome sequencing studies have revealed both
well-characterised and novel genomic alterations, with extensive
work performed in more advanced disease [23–26]. The most com-
monly altered genes in muscle-invasive urothelial carcinoma are
listed in Table 2 and Fig. 1 [27–65].
TP53
The p53 protein, encoded by the TP53 gene on chromosome
17p13.1, regulates DNA repair, apoptosis, senescence, growth
arrest, and metabolic homeostasis [27]. P53 functions as a tumour
suppressor through transcriptional activation of the p21
cyclin-dependent kinase inhibitor (CDKI) and subsequent inhibi-
tion of the G1-S cell cycle transition [66,67]. In the TCGA study data
set, approximately 59% of patients had a genomic alteration in thisgene (Table 2), making it the most commonly altered gene [25].
Heterozygosity at the 17p locus, with loss of function of the second
allele, leads to a paradoxical stabilisation and overexpression of the
defective protein in the nucleus of bladder cancer cells, leading to
ready assessment of p53 status by immunohistochemistry in more
than 90% of mutated cases [68,69]. Assessment of the TP53 gene by
sequencing or immunohistochemistry lends itself to a unique tar-
geted therapy approach using Wee-1 inhibitors such as MK-1775
[28,29], although its efﬁcacy has not yet been studied in urothelial
carcinoma. Wee1 is a tyrosine kinase that phosphorylates and
inactivates CDC2 and is involved in G2 checkpoint signalling.
Because p53 is a key regulator in the G1 checkpoint,
p53-deﬁcient tumours rely only on the G2 checkpoint after DNA
damage. Hence, such tumours are selectively sensitised to
DNA-damaging agents by Wee1 inhibition. In addition, recent ret-
rospective data suggest that patients with TP53 mutations may
beneﬁt from anti-angiogenesis agents such as bevacizumab, per-
haps because TP53 inhibits the transcription of VEGF-A (the target
of bevacizumab), which may be upregulated in the presence of the
mutation [30,70]. Bevacizumab demonstrated a RR in renal cell
carcinoma of approximately 31% [71].MLL2
The MLL2 gene (also called KMT2D) is a histone methyltrans-
ferase and a key regulator of histone H3 lysine 4 residue methyla-
tion [31]. Mutations in MLL2 are present in approximately 27% of
urothelial carcinoma cases [25]. Menin-MLL inhibitor is a promis-
ing agent to targetMLL2 aberrations and has demonstrated activity
in a pre-clinical acute leukaemia model [32].ARID1A
The ARID1A gene is a DNA-binding subunit of SWI/SNF com-
plexes and regulates gene expression through chromatin remod-
elling [33]. About 25% of urothelial carcinoma showed
loss-of-function mutations of ARID1A [25]. Currently, no agent
speciﬁcally targets the chromatin remodelling function of
ARID1A. Recent data, however, suggest that ARID1A mutation can
also sensitise cells to PI3K and AKT inhibitors, providing a venue
for actionability [34].KDM6A
The KDM6A gene (also known as UTX) is a histone demethylase
speciﬁc for histone H3 Lysin 27 and regulates gene transcription
[35]. In approximately 24% of urothelial carcinoma, KDM6A is
altered. There is no available targeted agent for KDM6A.
Table 2
Commonly mutated genes in muscle-invasive urothelial carcinoma [27–65].
Gene Frequency Pathway Function Examples of targeted agent Comment
TP53 59% p53
pathway
Tumour suppressor gene, regulates cell cycle, apoptosis, DNA
repair, senescence, and metabolism [27]
MK-1775 (Wee-1
inhibitor)[28]
Phase II in progress [29]
Bevacizumab Retrospective study in diverse tumours: 8 months PFS beneﬁt
[30]
MLL2 27% Histone
modiﬁcation
Histone methyltransferase, regulates transcription via chromatin
remodelling [31]
Menin-MLL inhibitor Activity in pre-clinical model [32]
ARID1A 25% SWI/SNF
complexes
A member of SWI/SNF complex, has helicase and ATPase
activities, regulates gene expression [33]
PI3K and AKT inhibitors Activity in pre-clinical model [34]
KDM6A 24% Histone
modiﬁcation
Histone demethylase, speciﬁc to Lys-27 of histone H3, regulates
transcription [35]
Not available
PIK3CA 20% PI3K
pathway
Catalytic domain of PI3K, a serine-protein kinase, regulates cell
proliferation, growth, migration, metabolism, and apoptosis [36]
Everolimus (mTOR
inhibitor)[37].
Multiple PIK3CA and AKT in-
hibitors in development [38–
43]
Case report of complete response for 14 months in patient with
mTOR mutation treated with everolimus and pazopanib [44]
EP300 15% Histone
modiﬁcation
Functions as histone acetyltransferase, regulates transcription by
chromatin remodelling [45]
Mocetinostat (HDAC inhibitor) Currently in phase II study [46]
CDKN1A 14% CDK/Rb
pathway
Negative regulator of cell cycle [47] PHA-848125AC (CDK2
inhibitor)
Currently in phase II for malignant thymoma [48]
RB1 13% CDK/Rb
pathway
Regulates G1-S phase progression, as well as transcription [49] HLM006474 (E2F inhibitor) Pre-clinical study showed activity [50]
ERCC2 12% DNA repair DNA helicase involved in DNA repair by nucleotide excision repair
[51]
Platinum Sensitises to platinum in urothelial carcinoma [52]
FGFR3 12% Receptor
tyrosine
kinase
Receptor tyrosine kinase, regulates cell proliferation,
differentiation, and apoptosis [53]
BGJ398 Phase I: 4 of 5 patients with urothelial cancer and FGFR
mutations had regression [54]
JNJ-42756493 Phase I: partial response in a patient with urothelial cancer and
FGFR abnormality [55]
BAY1163877 Phase I in progress [56]
Lucitanib Phase I in progress [57]
Ponatinib Activity in preclinical model [58]
BIBF 1120 Phase III for other malignancies [59]
Brivanib Phase II for other malignancies [60]
Lenvatinib Phase II for other malignancies [61]
STAG2 11% Chromatin
complex
A component of cohesin complex, a complex required in cell
replication [62]
Not available
HER2/HER3 Mutation
HER2: 0–9%
HER3: 0–11%
Ampliﬁcation/
overexpression:
HER2: 6–15%
Receptor
tyrosine
kinase
Regulates cell proliferation, growth, and migration [63] Trastuzumab A phase II study showed 70% RR in urothelial carcinoma [64]
Lapatinib A phase I study showed 74% RR in urothelial carcinoma [65]
Abbreviations: IHC = immunohistochemistry; RR = response rate.
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Fig. 1. Examples of important signalling pathways in urothelial carcinoma.
Tyrosine kinase receptors such as EGFR, HER2, HER3, and FGFR3 activate the MAP
kinase pathway (RAS-RAF-MEK) and the PI3K (PIK3CA-AKT-mTOR) pathways and
lead to cell proliferation. Also, aberrations of cell cycle regulatory pathways (TP53,
CDKN1A, CDKN2A, CCND1, CCNE1, RB1, and E2F3) increase cell proliferation. Lastly,
abnormalities in histone modiﬁcation factors (such as MLL2, ARID1A, and KDM6A)
are observed in urothelial carcinoma. For common mutations, see Table 2. Genes
frequently mutated/aberrant in urothelial tumours are in red.
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The PIK3CA gene encodes one of the catalytic subunits of
phosphoinositide-3 kinase (PI3K), and a protein complex regulates
cell proliferation, cell growth, apoptosis, and metabolism [36].
Upstream activation of PI3K by receptor tyrosine kinase or
G-protein coupled receptor activity results in conversion of phos-
phatidylinositol bisphosphate (PIP2) to phosphatidylinositol
triphosphate (PIP3) and subsequent AKT and mammalian target
of rapamycin (mTOR) activation [72,73]. Mutations of PIK3CA occur
in approximately 20% of urothelial carcinoma [25], and often
include gain-of-function mutations that involve the helical and
kinase domain [74]. Multiple agents are available that can target
PI3K and its major downstream effectors, AKT and mTOR. For
example, everolimus (RAD001) binds to FKBP2 and exerts its
effects primarily on the mTOR complex 1 (mTORC1) signalling
complex; although used in a number of cancer types, phase II stud-
ies in metastatic urothelial cancer patients showed only a 4%
response rate; protein expression did not correlate with response
but mutations were not assessed [37]. In a different trial, one
patient with urothelial carcinoma showed an extraordinary
response to everolimus and pazopanib, a receptor tyrosine kinase
inhibitor, and this correlated with an mTOR mutation [75]. Other
PI3K pathway-targeted agents (buparlisib for PI3K; triciribine,
MK-2206 for AKT; temsirolimus, sirolimus, and rapamycin for
mTOR) are currently under investigation in urothelial carcinoma,
although patients are not being selected on the basis of
PI3K/Akt/mTOR pathway mutation status [38–43,76].
EP300
The EP300 gene is a histone acetyltransferase, that regulates
gene transcription through chromatin remodelling in a manner
similar to ARID1A [45]. The EP300 gene is mutated in approxi-
mately 15% of urothelial carcinomas [25]. Loss-of-function muta-
tions of EP300 have been reported in lung, breast, ovarian,
pancreatic, and colorectal cancer [45]. Currently, no targeted ther-
apy is available for EP300mutations. However, histone deacetylase
inhibitors, such as vorinostat, have been associated with increased
therapeutic response in lymphoma cell lines that contain EP300
and CREBBP mutations [77]. One histone deacetylase inhibitor,
mocetinostat, is currently in a phase II study of advanced urothelialcarcinoma for tumours that harbour mutations in CREBBP and/or
EP300 [46].
CDKN1A
The CDKN1A gene encodes p21, an inhibitor of CDK1 and CDK2
(but not CDK4 or CDK6) and upstream regulator of p53 function.
p21 regulates the cell cycle, DNA repair, and apoptosis [47].
CDKN1A is mutated in approximately 14% of urothelial carcinoma
within the TCGA dataset [25]. Loss of p21 expression (via alter-
ations in the p21WAF1/CIP1 gene) may potentiate effects of TP53
mutation in bladder cancer and can itself serve as an independent
predictor of progression in bladder cancer [78,79]. Although no
direct inhibitor of p21 or its signalling pathway is currently under
clinical trial for urothelial carcinoma, the use of the CDK2 inhibitor
PHA-848125AC is currently being studied in a phase II setting for
malignant thymoma [48].
Rb
The retinoblastoma (Rb) gene, situated at chromosome 13q14,
is a prominent tumour suppressor gene in urothelial carcinoma
and is critical in regulating G1-S transition of the cell cycle [80].
Rb, once phosphorylated by cyclin dependent kinase (CDK) com-
plexes, exerts its effects by release of the associated E2F transcrip-
tion factor and initiation of the cell cycle [49]. The Rb gene is
inactivated in many cancers [49], and it is mutated in approxi-
mately 13% of urothelial carcinoma [25]. Additional alterations of
Rb in bladder cancer include deletions, hyperphosphorylation and
loss of negative upstream regulation [78,81]. An E2F inhibitor is
currently under development, with one preclinical study showing
this inhibitor to reduce cell proliferation and increased apoptosis
in a melanoma cell culture model [50].
ERCC2
Excision Repair Cross Complementation Group 2 (ERCC2)
encodes a DNA helicase that can repair single-strand DNA damage
by nucleotide excision repair [51]. Mutations of ERCC2 are
observed in approximately 12% of urothelial carcinomas [25], and
inactivating mutation is associated with increased response in
platinum treatment in urothelial carcinoma [52]. The combination
of single-strand damage repair and double-strand break repair may
enhance cell death in a manner similar to that seen with BRCA
mutations and response to PARP inhibitors and platinums [82].
FGFR3
Fibroblast growth factor receptor 3 (FGFR3) encodes a receptor
tyrosine kinase that regulates cell proliferation, differentiation,
and apoptosis [53]. FGFR3 signals through the RAS-MAP kinase
and PI3K pathways and has been shown to be critical in
low-grade non-invasive urothelial carcinomas, as well as in
high-grade invasive disease [83,84]. In advanced urothelial carci-
noma, FGFR3 is mutated in approximately 15–35% of cases
[25,83]. In a recent phase I trial using a pan-FGFR inhibitor
BGJ398, 4 out of 5 urothelial carcinoma patients with demon-
strated FGFR3-activating mutation showed tumour regression
[54]. In another study, a urothelial carcinoma patient with
FGFR3-TACC3 fusion showed a partial response to the pan-FGFR
inhibitor JNJ-42756493 [55]. Currently, expansion of the cohort is
underway in the JNJ-42756493 phase I study, and an upcoming
phase I trial for BAY1163877, another pan-FGFR inhibitor, is in pro-
cess [56]. Additional studies that combine anti-angiogenic and
FGFR targeted therapy have also been performed. In a phase II trial
of advanced urothelial carcinoma with or without FGFR3mutation,
Fig. 2. Proportion of molecular targeted therapy in current clinical trials for
urothelial carcinoma. Only 12% of trials use a biomarker approach for selecting
patients. A search in the clinicaltrial.gov web site (searched in https://clinicaltri-
als.gov; search term: [urothelial cancer OR bladder cancer]; study type: interven-
tional studies; ﬁrst received: 1/1/2012 and 1/1/2015), revealed that there were 223
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strated no clinical response in the FGFR3mutated group and only 1
out of 31 partial responses in the non-mutated groups [85].
Lucitanib is a novel dual inhibitor for VEGFR and FGFR, and is cur-
rently under study in a phase I trial [57]. Ponatinib is a multitar-
geted tyrosine kinase inhibitor including FGFRs, and currently
approved by the FDA for T315I-positive chromic myelogenous leu-
kaemia or T315I-positive Philadelphia chromosome positive acute
lymphoblastic leukaemia. Ponatinib inhibits tumour growth in an
urothelial carcinoma xenograft model [58]. Other FGFR inhibitors,
such as BIBF 1120, BMS-582664, and lenvatinib, are in phase II–
III clinical trials, but to our knowledge, urothelial carcinoma is
not included [59–61].
STAG2
Stromal antigen 2 (STAG2) encodes a subunit of the cohesion
complex, and regulates chromatoid cohesion and segregation
[62]. In the TCGA dataset, approximately 11% of urothelial carci-
noma exhibited mutations [25]. The therapeutic implication of
STAG2 alterations remains unclear.
HER2/neu (ErbB2)
The ErbB family encompasses EGFR (ErbB1; HER1), HER2/neu
(ErbB2), HER3 (ErbB3), and ErbB4, which represent tyrosine kinase
receptors [86]. HER2 has been studied extensively in urothelial car-
cinoma, where it has been proposed to function as an oncogene
[63,87]. HER2 forms a homodimer or a heterodimer with other
ErbB family members, with resultant activation of downstream
signalling pathways, such as MAP kinase, PI3 kinase, and MYC
[63,87]. In urothelial carcinoma, mutations were observed in both
HER3 (0–11%) and HER2 (0–9%) [88–90]. Overexpression or ampli-
ﬁcation in HER2 is seen in 6–15% of tumours [91,92]. Mutation of
HER2 is associated with higher complete pathologic response in
neoadjuvant chemotherapy [93]. HER2 gene alterations and resul-
tant protein products can be targeted by HER2-directed therapy,
such as trastuzumab, lapatinib, pertuzumab, and trastuzumab
emtansine [63]. A single-arm phase II study with trastuzumab,
paclitaxel, carboplatin, and gemcitabine for advanced urothelial
carcinoma demonstrated an overall response rate of 70% in the
HER2 positive population [64]. The efﬁcacy of trastuzumab is cur-
rently being tested in a randomised phase II study [94]. Lapatinib
is currently under evaluation in a phase II study of patients with
urothelial carcinoma [95].interventional trials for urothelial carcinoma. After excluding intervention trials for
life-style, diagnostic imaging, surgical procedure, or other malignancies, 96 trials
remained. Among these trials, molecular targeted therapy was included in 37 trials
(39%). Among molecular targeted therapy trials, only 11 trials (12% of total trials
[N = 96]) sought to enroll patients based on identiﬁed biomarker alterations rather
than including all patients with urothelial carcinoma. The remaining studies
included cytotoxic chemotherapy in 35 trials (36%) and immunotherapy (including
BCG) in 24 trials (25%).Immunotherapy
Novel immunotherapy agents have shown promising activities
in advanced urothelial carcinoma (Table 3) [96–104]. In 2011, ipil-
imumab became the ﬁrst new-generation immunotherapy to beTable 3
Emerging immunotherapy in urothelial carcinoma.
Name Company Category
Ipilimumab Bristol-Myers Squibb CTLA-4 inhibitor
MPDL3280A Roche PD-L1 inhibitor
MEDI4736 AstraZeneca PD-L1 inhibitor
Pembrolizumab Merck PD-1 inhibitor
Nivolumab Bristol-Myers Squibb PD-1 inhibitor
AMP-224 Amplimmune PD-1 inhibitorapproved by the FDA for melanoma [105]. Ipilimumab blocks the
immune checkpoint receptor cytotoxic T lymphocyte antigen 4
(CTLA4), and activates cytotoxic T cells [106]. In the melanoma
trial, ipilimumab prolonged overall survival and, more importantly,
led to long-term durable response in a subset of patients [105]. In
urothelial carcinoma, preoperative administration of ipilimumab
showed the mobilisation of CD4+ICOShigh T-cells in resected speci-
mens in 12 patients [96]. A a phase II study of ipilimumab with
gemcitabine and cisplatin for advanced urothelial carcinoma as a
ﬁrst line treatment is currently in progress [97]. Approaches using
anti-PD1 or anti-PD-L1 targeting, which block immune recognition
of cancer cells, are also showing encouraging results. For example,
MPDL3280A is an anti-PD-L1 monoclonal antibody that activates
T-cells. A phase I study with MPDL3280A in pretreated metastatic
urothelial carcinoma patients yielded an overall response rate of
50% in the PD-L1 positive group and 11% in the PD-L1 negative
group [98,107]. Of interest, PD-L1 positivity may be a biomarker
for response to anti-PD1 therapy in a variety of tumours, with
response rates of about 0–17% for PD-L1 negative tumours and
36–100% in PD-L1-positive tumours by immunohistochemistryComment
Mobilised T-cells in bladder cancer [96], currently in phase II trial [97]
Overall response rate 50% in PD-L1 positive pretreated advanced urothelial
carcinoma [98]; currently in phase II trial [99]
Currently in phase I trial [100,101]
Currently in phase III trial [102]
Currently in phase II trial [103]
Completed phase I trial [104]
704 S. Ikeda et al. / Cancer Treatment Reviews 41 (2015) 699–706[108]. A phase II study with MPDL34280A in advanced urothelial
carcinoma is currently recruiting patients [99]. Other PD1 or
PD-L1 inhibitors are under development (Table 3) [100–104].
Future direction
Molecular and immunologically targeted therapy is revolution-
ising the ﬁeld of oncology. For instance, trastuzumab has change
the standard of care in HER2/neu positive breast cancer patients
[109]. Discovery of the EGFR mutation and ALK rearrangement in
non-small cell lung cancer have led to more effective, and less toxic
targeted therapies [21]. However, despite the discovery of poten-
tially targetable gene alterations in urothelial carcinoma, most cur-
rent therapies were developed without patient selection strategies.
There is currently no FDA-approved agent that can target urothelial
carcinoma based on molecular or immunologic proﬁles. Indeed, in
the list of currently registered clinical trials in clinicaltrials.gov
(1/1/2012 and 1/1/2015), only 12% include targeted therapy appli-
cation matched to the appropriate molecular/biologic alterations,
indicating signiﬁcant room for improvement (Fig. 2).
So, where are we heading? It is conceivable that more improve-
ment can be achieved through the pursuit of molecular targeted
therapy similar to that for breast and lung cancer. However, it is
challenging to design clinical trials of molecular targeted therapy,
because of low mutation percentages and small populations.
Perhaps a cooperative effort to design a ‘smart trial’, such as a bas-
ket trial or an umbrella trial, would work for subsets of genomic
alterations [110], and could be expanded to include
non-mutational alterations known to affect protein behaviour,
including ampliﬁcation, phosphorylation status, or other similar
parameters. Finally, it is apparent that agents such as immunother-
apy that targets PD1/PDL1 can have potent effects in urothelial
malignancies, with response rates as high as 50% in individuals
that harbour tumours overexpressing PDL1 [98,107].
In summary, there is an expanding knowledge base of immuno-
logical, mutational, and other genomic and proteomic alterations
in urothelial carcinoma, as well as in other variants of bladder can-
cer. Interrogation of tumours for appropriate biomarkers and
matching of patients to the right agents, as well as awareness of
the complex genomic and proteomic milieu of bladder cancer, will
be required in order to improve outcomes.
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